Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

189.45 -0.23 (-0.12%)
Official Closing Price Updated: 7:00 PM EDT, Oct 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,131,540
Open 190.49
Bid (Size) 187.83 (1)
Ask (Size) 189.81 (1)
Prev. Close 189.68
Today's Range 188.51 - 191.16
52wk Range 135.85 - 199.95
Shares Outstanding N/A
Dividend Yield 3.12%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Momentum Trades For The Q4 Rally
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and stock, currently up 33.68% YTD. 
Via Benzinga

Performance

YTD
+18.54%
+18.54%
1 Month
-4.07%
-4.07%
3 Month
+1.43%
+1.43%
6 Month
+16.48%
+16.48%
1 Year
+33.52%
+33.52%

More News

Read More
Sweetgreen, Tesla, Digital Realty Trust And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
Via Talk Markets
Topics ETFs
3 Dividend Growth Stocks You Can Buy and Hold Forever
Via The Motley Fool
Forecasting The Future: 11 Analyst Projections For AbbVie
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
Market Analysis: AbbVie And Competitors In Biotechnology Industry
Via Benzinga
Looking Into AbbVie's Recent Short Interest
Via Benzinga
3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees
Via The Motley Fool
Beat the Nasdaq With This Cash-Gushing Dividend Stock
Via The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
Via The Motley Fool
Topics ETFs
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
Via Talk Markets
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
Via Benzinga
AbbVie's Options: A Look at What the Big Money is Thinking
Via Benzinga
3 Growth Stocks That Could Be Bargain Buys Right Now
Via The Motley Fool
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
Via Benzinga
Exposures Product Safety
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
Via Benzinga
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Via Benzinga
2 Magnificent Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Via MarketBeat
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Via Talk Markets
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.
Via The Motley Fool
Topics Stocks
Exposures US Equities
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.